{"id":"taribavirin","rwe":[{"pmid":"35296886","year":"2022","title":"Contemporary and emerging pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease.","finding":"","journal":"The Journal of antimicrobial chemotherapy","studyType":"Clinical Study"},{"pmid":"31346920","year":"2020","title":"Viramidine-Loaded Galactosylated Nanoparticles Induce Hepatic Cancer Cell Apoptosis and Inhibit Angiogenesis.","finding":"","journal":"Applied biochemistry and biotechnology","studyType":"Clinical Study"},{"pmid":"29488022","year":"2018","title":"Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"},{"pmid":"27769407","year":"2016","title":"Online solid phase extraction and liquid chromatography-mass spectrometric determination of nucleoside drugs in plasma.","finding":"","journal":"Talanta","studyType":"Clinical Study"},{"pmid":"25473172","year":"2014","title":"Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.","finding":"","journal":"World journal of gastroenterology","studyType":"Clinical Study"}],"tags":[{"label":"taribavirin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ribamidine","offLabel":[],"synonyms":["taribavirin hydrochloride","taribavirin","ribamidine","viramidine","taribavirin HCl"],"timeline":[],"approvals":[],"brandName":"Ribamidine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"taribavirin","explanation":"Think of it like a copy machine. Viruses make copies of themselves to spread, and Ribamidine tries to stop that process. It's like jamming the copy machine so it can't make more copies.","oneSentence":"Ribamidine works by inhibiting viral replication, although the exact mechanism is unknown.","technicalDetail":"Ribamidine is a nucleoside analog that is phosphorylated to its active form, which then inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3582","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TARIBAVIRIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TARIBAVIRIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:46:51.925402","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:29.400504+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"taribavirin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00446134","phase":"PHASE2","title":"Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-03","conditions":["Chronic Hepatitis C"],"enrollment":278,"completionDate":"2009-04"},{"nctId":"NCT00093093","phase":"PHASE3","title":"Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-06","conditions":["Chronic Hepatitis C"],"enrollment":900,"completionDate":"2006-05"},{"nctId":"NCT00305383","phase":"PHASE2","title":"Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-11","conditions":["Hepatitis C, Chronic"],"enrollment":100,"completionDate":"2007-05"},{"nctId":"NCT00230958","phase":"PHASE3","title":"Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2003-12","conditions":["Chronic Hepatitis C"],"enrollment":900,"completionDate":"2006-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"R3B1994K2E","CHEBI":"CHEBI:134989","INN_ID":"8619","UMLSCUI":"C0073221","ChEMBL_ID":"CHEMBL2111108","KEGG_DRUG":"D06651","DRUGBANK_ID":"DB06408","PDB_CHEM_ID":"R1Y","PUBCHEM_CID":"451448","SECONDARY_CAS_RN":"40372-00-7","MESH_SUPPLEMENTAL_RECORD_UI":"C026956"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":17,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2022 May 29","pmid":"35296886","title":"Contemporary and emerging pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease.","journal":"The Journal of antimicrobial chemotherapy"},{"date":"2020 Jan","pmid":"31346920","title":"Viramidine-Loaded Galactosylated Nanoparticles Induce Hepatic Cancer Cell Apoptosis and Inhibit Angiogenesis.","journal":"Applied biochemistry and biotechnology"},{"date":"2018 Feb 27","pmid":"29488022","title":"Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer.","journal":"Pharmaceutical research"},{"date":"2016 Dec 1","pmid":"27769407","title":"Online solid phase extraction and liquid chromatography-mass spectrometric determination of nucleoside drugs in plasma.","journal":"Talanta"},{"date":"2014 Nov 21","pmid":"25473172","title":"Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.","journal":"World journal of gastroenterology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribamidine is a small molecule with no verified information on its mechanism of action. It has been studied in combination with other treatments for Chronic Hepatitis C, Hepatitis C, and Chronic Hepatitis C in clinical trials.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:29.400504+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}